Novartis' Kisqali sharpens survival edge with second ph3 win

In a phase 3 study, Kisqali significantly extended the lives of post-menopausal women with HR-positive, HER-2 negative breast cancer, the Swiss drugmaker said Wednesday. The group included both previously untreated women and women who had already failed on one prior therapy.